Blood pressure (BP) control rates are known to be insufficient worldwide. Although some improvement has occurred over time, 1 the lack of BP control has a prevalence of approximately 60% in European countries 2 and >50% in the United States. 1 As regards subclinical target organ damage, left ventricular hypertrophy is associated with worse BP control, 3 and the relationship between urinary albumin excretion (UAE) and BP levels has also been widely explored. Thus, analyses of the data from the National Health and Nutrition Examination Survey have shown an association between microalbuminuria and uncontrolled office BP in a hypertensive population when the cutoff of 30 mg/g of UAE to define microalbuminuria was used, 1,4 regardless of the degree of renal function. On the other hand, several studies have shown the prognostic value of albuminuria for overall mortality and cardiovascular and renal morbidity at levels of UAE well below the cutoff point of 30 mg/g. [5] [6] [7] Recently, the meta-analysis by Hallan et al. 7 that evaluated large cohorts of general population, vascular high-risk patients, and individuals with chronic kidney disease showed that the association of UAE with end-stage renal disease and mortality risks was linear with no threshold. In agreement with this, the division of normoalbuminuria into 2 different categories-optimal UAE (<10 mg/g) and high-normal UAE (10-29 mg/g)-has been proposed. 8 However, it is unclear whether the relationship between BP and UAE is different between patients with optimal and high-normal UAE. Accordingly, we hypothesize that UAE could be associated with office BP control at levels lower than those that define microalbuminuria (i.e., 30 mg/g) in patients with treated hypertension. Although elevated urinary albumin excretion (UAE) is associated with cardiovascular prognosis and high blood pressure (BP), it is unknown whether differences in BP control could also exist between patients with different grades of UAE, even in the normal range. We sought to explore the association between different levels of UAE and BP control in treated hypertensive patients.
Blood pressure (BP) control rates are known to be insufficient worldwide. Although some improvement has occurred over time, 1 the lack of BP control has a prevalence of approximately 60% in European countries 2 and >50% in the United States. 1 As regards subclinical target organ damage, left ventricular hypertrophy is associated with worse BP control, 3 and the relationship between urinary albumin excretion (UAE) and BP levels has also been widely explored. Thus, analyses of the data from the National Health and Nutrition Examination Survey have shown an association between microalbuminuria and uncontrolled office BP in a hypertensive population when the cutoff of 30 mg/g of UAE to define microalbuminuria was used, 1, 4 regardless of the degree of renal function. On the other hand, several studies have shown the prognostic value of albuminuria for overall mortality and cardiovascular and renal morbidity at levels of UAE well below the cutoff point of 30 mg/g. [5] [6] [7] Recently, the meta-analysis by Hallan et al. 7 that evaluated large cohorts of general population, vascular high-risk patients, and individuals with chronic kidney disease showed that the association of UAE with end-stage renal disease and mortality risks was linear with no threshold. In agreement with this, the division of normoalbuminuria into 2 different categories-optimal UAE (<10 mg/g) and high-normal UAE (10-29 mg/g)-has been proposed. 8 However, it is unclear whether the relationship between BP and UAE is different between patients with optimal and high-normal UAE. Accordingly, we hypothesize that UAE could be associated with office BP control at levels lower than those that define microalbuminuria (i.e., 30 mg/g) in patients with treated hypertension. Thus, we aimed to analyze the association between BP control and treated hypertensive patients categorized into different levels of UAE. We wanted also to explore whether differences in BP control exist for different levels of UAE even in the normal range.
METHODS

Study population
Patients aged ≥18 years with essential hypertension diagnosed according to current guidelines 9 (at least 3 BP measurements taken on separate occasions with systolic and/or diastolic BP ≥140 mm Hg and/or 90 mm Hg, respectively) were recruited consecutively from 36 specialized hypertension clinics in Spain (for the full list of investigators, please see the Supplementary Material). Exclusion criteria were known secondary hypertension and any cardiovascular event developed within the 3 months before inclusion. The study protocol conforms to the principles outlined in the Declaration of Helsinki and was approved by all local institutional ethic committees. Informed consent was obtained from all participants before their inclusion in the study.
Demographic and anthropometric characteristics, cardiovascular risk factors, and laboratory results were recorded in the inclusion visit from all participants, and the following data were obtained: age, sex, weight, height, and waist circumference. Obesity was defined by a body mass index ≥30 kg/m 2 , and abdominal obesity was defined by a waist circumference >102 cm in men or >88 cm in women. Other recorded variables were smoking habit, duration of hypertension, antihypertensive treatment prescribed, family history of premature cardiovascular disease, and personal previous history of cardiovascular disease (including cerebrovascular disease, coronary heart disease, heart failure, symptomatic ischemic peripheral vascular disease, and advanced hypertensive retinopathy as defined by hemorrhages, exudates, or papilledema). Diabetes mellitus was diagnosed using medical history if the patient was under antidiabetic treatment or if the patient had ≥2 fasting plasma glucose determinations ≥7.0 mmol/L. Dyslipidemia was considered if patients were being treated with lipid-lowering drugs and/or total cholesterol was >5 mmol/L, low-density lipoprotein cholesterol was >3.0 mmol/L, high-density lipoprotein cholesterol was <1.0 mmol/L (men) or <1.2 mmol/L (women), or triglycerides were >1.7 mmol/L. Serum creatinine was measured by an enzymatic modified Jaffe reaction (Roche Diagnostics, Basel, Switzerland), consistent with the current recommendations for standardizing serum creatinine measurement. The estimated glomerular filtration rate (eGFR) was calculated by using the Chronic Kidney Disease-Epidemiology Collaborative (CKD-EPI) equation: 10 
BP measurement
Office BP was measured at the inclusion visit in accordance with the current guidelines. 9 After a minimum of 5 minutes of seated rest in a quiet room, BP was obtained by averaging 2 office measurements spaced by 1-2 minutes using a validated oscillometric semiautomatic device or a mercury sphygmomanometer with regular or large adult cuffs used as needed. Controlled BP was defined by systolic BP (SBP) <140 mm Hg and diastolic BP (DBP) <90 mm Hg.
Urinary albumin excretion
UAE (measured by turbidimetry in local laboratories according to current recommended standards; averaged maximum intra-assay and inter-assay variation coefficients of 1.2% and 4.4%, respectively) was determined as the average of the ratio of concentration of albumin to creatinine in 2 spot first-morning void urine samples obtained on separate days. Albuminuria was categorized into 4 groups: G0 (UAE <10 mg/g), G1 (UAE ≥10 and <30 mg/g), G2 (UAE 30-299 mg/g), and G3 (UAE ≥300 mg/g).
Statistical analyses
The sample size was calculated to detect a 10% difference in the proportion of controlled patients between subjects with or without microalbuminuria (cutoff value of 30 mg/g). Three hundred seventy-six patients per group were required to detect such a 10% difference with a bilateral alpha error of 0.05 and a statistical power of 80%. Because the estimated prevalence of microalbuminuria would be approximately 30%, we decided to include a total of 1,200 patients to have between 350 and 400 patients with microalbuminuria. Exploring differences between patients with normal or highnormal UAE was not submitted to a power calculation, but with a minimum of 300 patients per group, a 10% difference would have a statistical power of 70%.
Continuous variables are summarized by mean ± SD if normally distributed or by median (interquartile range) otherwise. Categorical variables are described as frequencies and percentages. Bivariable comparisons between patients with BP control and patients with lack of BP control were performed by unpaired t tests in continuous data, by the nonparametric Mann-Whitney test in asymmetrically distributed data, and by χ 2 test in categorical data. The association between UAE and BP was assessed with the Spearman correlation coefficient. χ 2 was also used to explore differences among the 4 groups of UAE. Pairwise comparisons between groups were corrected by the Bonferroni method. A logistic regression explored the association between groups of UAE and lack of BP control after adjustment for confounders (age, sex, obesity, duration of hypertension, diabetes, eGFR as categorized by the threshold of 60 ml/min/1.73m 2 , and previous cardiovascular disease). The odds ratio (OR) and correspondent 95% confidence intervals (CIs) for groups G1 to G3 were calculated with G0 as the reference. The SPSS for Windows version 19.0 software (IBM, Armonk, NY) was used for statistical analyses.
RESULTS
A total of 1,200 patients with treated essential hypertension entered the study. Mean age ± SD was 63 ± 12 years, and 41% of patients were women. The prevalence of type 2 diabetes mellitus was 36%, and obesity was diagnosed in 45% of all patients. The prevalence of UAE ≥30 mg/g was 33%, and 28% of patients had impaired renal function (eGFR by CKD-EPI < 60 ml/min/1.73 m 2 ).
Five hundred fourteen patients (42.8%) had BP above goal (i.e., their SBP and/or DBP was ≥140 and/or 90 mm Hg, respectively). Clinical characteristics and risk factors in patients with lack of BP control or controlled BP are compared in Table 1 . Patients with lack of BP control were older, more obese, and had a higher prevalence of diabetes mellitus. Median UAE (20.3 vs. 11.7 mg/g; P < 0.001) and the percentage of patients with UAE ≥30 mg/g (39.5 vs. 28.1%; P < 0.001) were significantly higher in patients with lack of BP control than in patients with controlled BP. There were no statistically significant differences between both groups as regards eGFR or percentage of patients with impaired renal function (i.e., eGFR <60 ml/min/1.73 m 2 ). As for the percentage of patients receiving treatment with renin-angiotensin-aldosterone system blockers (i.e., angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, or direct renin inhibitors), the figures were not significantly different between the groups. UAE significantly correlated with SBP (Rho = 0.15; P < 0.001) but not with diastolic BP (Rho = 0.01; P = 0.62). (see Supplementary Figure S1 ).
To further explore the association between UAE and BP control, lack of BP control was compared among the 4 groups of patients established according to the UAE. These data and the characteristics of patients belonging to each group are shown in Table 2 . There were significant differences in BP control among the 4 groups. The between-group comparisons yielded statistically significant differences in G2 (UAE 30-299 mg/g) vs. G0 (UAE <10 mg/g; P < 0.01) and G2 vs. G1 (10-29 mg/g; P < 0.05), but no statistically significant differences were observed in the comparison between G0 and G1 (P = 0.18) or between G2 and G3 (P = 0.48). Even though the lack of BP control in G3 (48%) was higher than in G0 (37%), the differences between G0 and G3 were not statistically significant (direct comparison P = 0.049; Bonferroni correction P = 0.29). Attending to the mean values of SBP and DBP, it can be observed that SBP, but not DBP, was significantly different between the 4 categorized groups of UAE (P < 0.001) ( Table 2) . Moreover a sensitivity analysis in groups with and without diabetes confirmed these results for both diabetic and nondiabetic patients (Supplementary Tables S1 and S2 ). Figure 1 shows the ORs (95% CIs) obtained for the association of each UAE group (G0 used as reference) with lack of BP control after adjustment for confounders (age, sex, obesity, duration of hypertension, diabetes, eGFR as categorized by the threshold of 60 ml/min/1.73m 2 , and previous cardiovascular disease). As shown, only the OR for G2 Data are given as mean ± SD, median (interquartile range), or frequencies and percentages. Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure; UAE, urinary albumin excretion.
a Abdominal obesity defined as waist circumference >102 cm (men) or >88 cm (women).
was statistically significant (OR = 1.40, 95% CI = 1.16-1.68; P < 0.001).
DISCUSSION
In this cohort of treated patients with essential hypertension, we found an overall prevalence of BP control of 57.2%. Urinary albumin excretion was significantly higher in patients with lack of BP control than in patients with BP under control, and patients with UAE ≥30 mg/g were at higher risk of having office BP values above goal (≥140 and/ or 90 mm Hg) than normoalbuminuric patients. The main novelty is that we have found no statistically significant differences as regards BP control between patients with optimal UAE (<10 mg/g) and patients with high-normal UAE (10-29 mg/g) in this cohort of treated hypertensive patients.
The low rate of BP control achieved worldwide is a wellknown problem, even in treated hypertensive patients, with almost half of these patients showing lack of BP control. 1, 2 Certain aspects related to the treatment may be responsible for lack of BP control, such as a poor adherence, therapeutic inertia, or an insufficient therapeutic effort including more use of combined treatment. 11 More than that, several clinical features have been shown to be more prevalent in patients with lack of BP control than in patients with BP at goal. Among the main factors associated with lack of BP control, the most commonly reported are older age, 1, 12, 13 obesity, 2,12-14 diabetes, 2,13 and established cardiovascular 15 or renal disease. [13] [14] [15] On the other hand, several large population studies 16, 17 and intervention studies 18 have reported on the association of increased UAE with high BP, and higher levels of UAE have been shown in patients whose BP is not controlled with antihypertensive treatment. 1, 4 This association is particularly evident for patients with chronic kidney disease [19] [20] [21] and patients with resistant hypertension. 13, 14, [22] [23] [24] Although in most of these studies such a correlation has been shown to be quite strong with 24-hour ambulatory BP but weaker with routine office BP, [16] [17] [18] 22, 23 2 recently published small studies reported similar correlations of microalbuminuria with either high-quality automated office BP 25 or community pharmacy BP and 24-hour ambulatory BP 26 readings. However, there is scarce information about this association for values of UAE below the lower cutoff used for the definition of microalbuminuria. In our study, we found that UAE correlated significantly with SBP, but not with DBP. This agrees with the known greater difficulty of controlling SBP compared with the control of DBP. 3 Furthermore, we observed a significant trend for a higher percentage of patients with lack of BP control with increasing UAE, with Data are given as mean ± SD or frequencies and percentages. Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure; UAE, urinary albumin excretion.
a Abdominal obesity defined as waist circumference >102 cm (men) or >88 cm (women). *P < 0.01 compared with G0 and P < 0.05 compared with G1. ** P < 0.05 compared with G0. the greater difference between patients with UAE <10 mg/g and patients with microalbuminuria. In addition, we demonstrated that the prevalence of patients with lack of BP control is significantly higher in patients with microalbuminuria than in patients with normoalbuminuria, with no statistically significant differences between patients with optimal UAE and patients with high-normal UAE. On the other hand, the nonsignificance shown for the comparisons of the percentage of uncontrolled patients in G3 vs. G0 and in G3 vs. G2 could be due to a probable major therapeutic effort in these G3 patients, who have an undoubtedly higher risk, as well as to a lower diastolic BP in G3. It must be noted that the sample size was adequate (80% power) for obtaining a difference of ≥10%. With the actual numbers, the comparison between G0 and G1 had a statistical power of 23%, whereas the comparison between G0 and G2 had a statistical power of 97%, and the comparison between G1 and G2 had a statistical power of 76%. Several studies have shown that low-grade albuminuria is associated with a higher risk of mortality and cardiovascular and renal disease in the general population, 27 in a community-based population of middle-aged nonhypertensive, nondiabetic individuals, 28 and in patients with high vascular risk. 29 Moreover, changes over time of UAE levels, even in the considered normal range, have been shown to be predictors of risk. 27, 29 This evidence justifies the importance of finding out whether this increased risk for small changes in albuminuria within the normal range is associated with the degree of BP control. Conversely, it is also important to disclose whether the association between BP control and UAE occurs at all levels of UAE or only from the lower limit of microalbuminuria up. Our results show that the control of BP in treated hypertensive patients does not substantially differ between patients with optimal or with high-normal UAE.
We must point to some limitations of our study. First, the antihypertensive treatment of these patients was not homogeneous. However, the percentage of patients receiving drugs capable of modifying UAE was very high throughout the entire cohort and similar for all the UAE-categorized groups, making it very unlikely that this interfered with the results. Second, because some studies in patients with resistant hypertension 23 or type 2 diabetes 30 have shown a close relationship between UAE and high nocturnal SBP, we cannot discard differences in nighttime BP control among patients with optimal UAE and those with high-normal UAE. The possibility of such an association in communitytreated hypertensive patients remains to be assessed in further studies.
On the other hand, as a strength of our study, we explored our hypothesis in a large cohort of individuals. Moreover, the UAE was measured twice in fresh morning urine samples, which implies a more accurate measurement than the mostly reported 1-time dipstick test, thus giving more robustness to our results.
In conclusion, we have demonstrated that UAE is associated with lack of BP control in treated hypertensive patients. Lack of office BP control is significantly more prevalent in patients with microalbuminuria than in patients with UAE within the normal range. Remarkably, we found no statistically significant differences for this association among patients with different degrees of normoalbuminuria (i.e., optimal or high-normal UAE), although the trend toward a difference in mean SBP between the groups means this should be further confirmed in larger studies. Despite the knowledge of the important clinical role of UAE in disease screening, as well as of its prognostic value, our results show that there is not enough evidence for a significant association between UAE and lack of BP control at a cutoff of UAE below the established lower limit that defines microalbuminuria.
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